Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (November 5th Preview)
-
AstraZeneca poised for major takeout of Rhythm Pharmaceuticals over Imcivree momentum
AstraZeneca is reportedly preparing to bid roughly $10 billion for Rhythm Pharmaceuticals, escalating deal speculation around the metabolic biotech and its commercial weight-loss asset, Imcivree (setmelanotide). The Wall Street Journal cited sources familiar with the matter, saying AstraZeneca offered about $124 per share, after Rhythm’s shares surged on the news. Imcivree’s traction appears central to the interest. The drug won FDA approval in March for acquired hypothalamic obesity (aHO), and Rhythm has positioned that indication as a likely growth driver. Earlier this week, Rhythm reported $92.1 million in global quarterly sales for Imcivree, up 29% quarter over quarter. Rhythm is also planning Phase 3 work in Prader-Willi syndrome, which could broaden the label further. Analysts at William Blair have flagged metabolic “takeout” appeal broadly, noting that GLP-1 therapies do not directly overlap the company’s injectable MC4-pathway positioning. The report follows a period in which Rhythm has been seen as a “hot ticket” because of its focused metabolic biology and late-stage optionality, putting Rhythm back in the center of big-pharma consolidation conversations.
-
AbbVie pays for Nxera’s gut-restricted EP4 agonist for IBD
AbbVie has signed a global licensing deal for Nxera Pharma’s gut-targeted EP4 receptor agonist, NXE0033744, betting that localized signaling can improve inflammatory bowel disease outcomes while reducing off-target exposure. Under the agreement, AbbVie is paying Nxera $100 million upfront through Nxera’s UK unit, with additional development and commercial milestones of up to $1.37 billion and tiered royalties. Nxera engineered NXE0033744 to restrict activation to the gastrointestinal tract by using an EP4 agonist designed for local effects. The company said a completed Phase 1 program showed reduced intestinal permeability in an indomethacin challenge cohort, consistent with the intended mechanism, with no concerning side effects reported during the program. The transaction uses Nxera’s NxWave drug discovery platform, which centers on designing small molecules for GPCR receptors. For AbbVie, the deal adds another immunology and gastroenterology program as the company continues to build out late-stage IBD opportunities. For the market, the economics underscore how big biopharma is valuing tissue-restricted approaches in inflammation, especially when they differentiate from systemic immunomodulation.
-
T-Therapeutics lands $133M megafunding for bispecifics targeting undruggable cancer and autoimmune disease
T-Therapeutics has raised $133 million in a funding round focused on bispecific antibodies, aiming to expand its platform for cancer targets that are difficult to drug and for selective autoimmune treatments. The company’s strategy emphasizes engineering that it claims can improve access to known but “undruggable” biology. The financing signals renewed investor appetite for modality-heavy companies where platform differentiation is central to the value proposition. For the biotech sector, it also highlights how bispecifics remain a core financing theme, particularly when startups can tie their molecule designs to clear clinical hypotheses. While the article does not detail a specific lead candidate or trial readout, the size of the round suggests T-Therapeutics is looking to accelerate discovery-to-clinic timelines and build out its preclinical portfolio. Investors will likely watch how the company converts its claimed selectivity and target reach into IND-enabling progress and early clinical proof points.
-
Alethio Therapeutics secures $90M Series A for first-in-class G6B antibody in essential thrombocythemia
Alethio Therapeutics has closed an oversubscribed $90 million Series A, providing runway for its lead program, ATX-011, into Phase I/IIa studies for essential thrombocythemia (ET). The University of Oxford spinout says the goal is to reach Phase III readiness after generating first-in-patient data. ATX-011 is designed as a first-in-class monoclonal antibody against G6B, a protein described as present on platelets and megakaryocytes. Alethio aims to lower platelet counts in ET by boosting platelet clearance and also highlights G6B expression on myeloproliferative neoplasm–initiating stem cells as part of a broader, mutation-agnostic mechanism. The company is positioning ATX-011 against current ET management, where options are limited and responses to hydroxyurea can be incomplete and slow. Alethio argues its approach could normalize hematopoiesis and reduce thrombotic risk while also targeting disease progression biology. Sofinnova Partners and RA Capital co-led the round, with Oxford Science Enterprises participating and Cancer Research Horizons and the University of Oxford providing additional support.
-
Clinical AI for trials: Boehringer Ingelheim and Microsoft explore AI ‘digital patient twins’ to cut control-group burden
Boehringer Ingelheim and Microsoft have launched a research collaboration to develop AI-powered “digital patient twins” to simulate disease progression and treatment response for clinical trial design. The teams want to test whether these models can serve as synthetic or hybrid control groups, potentially reducing the number of patients needed in controls. Boehringer said the work is exploratory but is intended to generate evidence that the simulated disease trajectories can predict relevant outcomes when grounded in clinical and other data. A Boehringer spokesperson told BioXconomy that any future use, including placebo-reduction concepts, would depend on scientific validation and applicable regulatory approvals. The collaboration is framed as part of a broader wave of trial-focused AI partnerships, following related industry moves such as AstraZeneca’s work with Oracle and Sanofi’s partnership with Formation Bio to accelerate recruitment in multiple sclerosis studies. The initiative also comes after HHS launched SURPASS, which includes digital patient twins for specific trial design and feasibility tasks.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.